HR+/HER2- early breast cancer

Clinical trials for HR+/HER2- early breast cancer explained in plain language.

Never miss a new study

Get alerted when new HR+/HER2- early breast cancer trials appear

Sign up with your email to follow new studies for HR+/HER2- early breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 9 Not yet recruiting 3 Not yet finished but already full! 1 Completed 1

New drug combo shows promise in shrinking Hard-to-Treat breast tumors

Disease control Completed

This study tested a new drug combination (fluzoparib plus chemotherapy) given before surgery to 28 women with a specific type of early breast cancer (HR+/HER2- with HRD). The goal was to see if it could shrink tumors more effectively. The treatment was given over 8 cycles, and th…

Matched conditions: HR+/HER2- EARLY BREAST CANCER

Phase 2 • Sponsor: Xijing Hospital • Aim: Disease control

Last updated Jun 27, 2026 12:07 UTC

HR+/HER2- early breast cancer

Get alerted when new HR+/HER2- early breast cancer trials appear

New drug combo shows promise in shrinking Hard-to-Treat breast tumors